|
|
Line 18: |
Line 18: |
| *Repeat expansion leads to '''anticipation: earlier onset of disease with each generation'''. | | *Repeat expansion leads to '''anticipation: earlier onset of disease with each generation'''. |
| *Some expansions become interrupted by a second codon sequence (like in Fragile X syndrome, CGGs are interrupted by AGGs); '''interrupted repeats are less likely to expand'''. | | *Some expansions become interrupted by a second codon sequence (like in Fragile X syndrome, CGGs are interrupted by AGGs); '''interrupted repeats are less likely to expand'''. |
| + | *In this group, some bases (e.g. a CAG triplet) are repeated in tandem multiple times (e.g.: (CAG)7). |
| | | |
| | | |
| *When repeats result in coding regions, they are called '''poly amino acid tracts'''. | | *When repeats result in coding regions, they are called '''poly amino acid tracts'''. |
| **It is estimated that 20% of human proteins contain a poly amino acid tract. | | **It is estimated that 20% of human proteins contain a poly amino acid tract. |
| + | *Poly amino acid tracts tend to manifest as neurologic disorders. |
| + | *Some poly amino acid tracts demonstrate anticipation. |
| *Poly amino acids tracts include: | | *Poly amino acids tracts include: |
| **[[Huntington disease]] | | **[[Huntington disease]] |
Line 52: |
Line 55: |
| | | |
| ====[[Charcot-Marie-Tooth Disease]]==== | | ====[[Charcot-Marie-Tooth Disease]]==== |
- |
| |
- | Unstable repeat expansion diseases (Grouped together based on the molecular etiology of mutant allele formation)
| |
- | In this group, some bases (e.g., a CAG triplet) are repeated in tandem multiple times (e.g., (CAG)7).
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | The repeat may be at various locations in the gene
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | Typically, disease symptoms are associated with increases in the number of repeats (i.e., expansion).
| |
- | …ATCATCAGCAGCAGCAGCAGCAGCAGTTGAGT…
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | Myotonic Dystrophy (Autosomal Dominant, Multisystem Disorder)
| |
- |
| |
- | Progressive muscle weakness and wasting, begins in face (masklike) then generalized
| |
- | Myotonia
| |
- | Can’t relax after contraction
| |
- | Early cataracts
| |
- | Cardiac involvement
| |
- | Conduction defects
| |
- | Endocrine/reproductive defects
| |
- | E.g., testicular atrophy
| |
- | Demonstrates “Anticipation”
| |
- |
| |
- |
| |
- | Most common inherited neuromuscular disorder of adult life
| |
- | Myotonic Female Face (600)
| |
- | Anticipation A phenomenon in which there is progressively earlier onset and/or increased severity of disease in successive generations of a family
| |
- |
| |
- |
| |
- |
| |
- | myotonic from t and t 300
| |
- | Three generations of a myotonic dystrophy family
| |
- | Fig 7-32 from Genetics in Medicine, Eds. Nussbaum McInnes, Willard
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | Exons 1-14 Exon 15
| |
- |
| |
- | Translation stop
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | Normal
| |
- | n = 5-35 repeats
| |
- |
| |
- | Mutation/expansion
| |
- | > 50 repeats
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | Myotonic Dystrophy (DMPK gene, DM protein kinase)
| |
- |
| |
- |
| |
- |
| |
- | (CTG)n
| |
- |
| |
- | 3’ UTR
| |
- | CTG expansion is in 3’ UTR (untranslated region, non-coding) part of gene. Therefore, the protein sequence is normal.
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | Alleles with 14 and 2100 repeats
| |
- | 24/69
| |
- |
| |
- | 5/84
| |
- |
| |
- | 5/75
| |
- |
| |
- | 13/112
| |
- | 13/205
| |
- | 5/160
| |
- | 13/300
| |
- | 16/200
| |
- | 14/2100
| |
- |
| |
- | 13/730
| |
- |
| |
- |
| |
- | I
| |
- |
| |
- | II
| |
- |
| |
- | III
| |
- |
| |
- | IV
| |
- |
| |
- | V
| |
- |
| |
- | Anticipation is explained at the molecular level because, in general, with larger expansions there is earlier onset and a more severe clinical picture
| |
- |
| |
- | Congential Myotonic Dystrophy: The congenital (severe) form of disease comes from maternal transmission. The largest expansions happen during female gametogenesis (gender specific).
| |
- |
| |
- |
| |
- |
| |
- | Alleles with 14 and 2100 repeats
| |
- | 24/69
| |
- | 5/84
| |
- | 5/75
| |
- | 13/112
| |
- |
| |
- | 13/205
| |
- |
| |
- | 5/160
| |
- |
| |
- | 13/300
| |
- | 16/200
| |
- | 14/2100
| |
- | 13/730
| |
- |
| |
- | There is instability in both germline and somatic cells, and, there can be reductions in size.
| |
- | I
| |
- |
| |
- | II
| |
- |
| |
- | III
| |
- |
| |
- | IV
| |
- |
| |
- | V
| |
- |
| |
- |
| |
- | •
| |
- | It is not simply haploinsufficiency
| |
- |
| |
- | •
| |
- | Mutant DMPK RNA accumulates in
| |
- |
| |
- |
| |
- | foci in the nucleus.
| |
- | –
| |
- | There is probably less DMPK protein
| |
- |
| |
- | –
| |
- | But, ….
| |
- |
| |
- |
| |
- | •
| |
- | Studies of mice –
| |
- | Knock-out mice do not mimic the
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | human disease
| |
- | –
| |
- | Mice with an expansion more closely
| |
- |
| |
- |
| |
- |
| |
- | mimic the human disease.
| |
- | –
| |
- | And, the repeat in a different context (i.e., associated with a different coding region) can still cause development of myotonia (in mice).
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | Myotonic dystrophy pathogenesis
| |
- | TIG 20(10) 2004 path RNA
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | Wide upward diagonal
| |
- |
| |
- | Coding region for Human Skeletal Actin
| |
- |
| |
- | Repeat from DMPK
| |
- |
| |
- |
| |
- | •
| |
- | “Expanded CUG repeats trigger aberrant splicing of CIC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy.” (E.g., Molecular Cell. 10:35) –
| |
- | CIC-1 is the main chloride channel in muscle.
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | •
| |
- | And there is another gene DM2 (Myotonic dystrophy type 2) –
| |
- | Accounts for a small % of cases
| |
- |
| |
- | –
| |
- | Mutation is in gene ZNF9
| |
- |
| |
- | –
| |
- | Mutation is an expansion of a CCUG in the first intron of ZNF9
| |
- |
| |
- | –
| |
- | Expansion of the CCUG in the first intron of ZNF9 also results in disrupted processing of RNA of other genes
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | Myotonic dystrophy pathogenesis (cont.)
| |
- | •
| |
- | This and other data supports a trans-dominant, RNA gain of (negative) function in myotonic dystrophy. (toxic RNA)
| |
- |
| |
- | •
| |
- | Probably the first well-documented example of this pathogenic mechanism in humans
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | AJHG 2004 74793 myotonic
| |
- | Summary: Multisystem disorder with complex pathogenesis
| |
- |
| |
- |
| |
- | Fragile-X Syndrome (Clinical Case Study #15)
| |
- |
| |
- |
| |
- | Called this because under certain conditions, an end of the X chromosome seems to be breaking off.
| |
- | frax chromo cartoon meh
| |
- | Mental retardation Physical Findings (males)
| |
- | Males moderate Head somewhat large before
| |
- | 3-6% of MR in boys with puberty
| |
- | positive family history of Prominent ears, jaw and forehead
| |
- | MR and no birth defects after puberty
| |
- | Females mild Macroorchidism
| |
- |
| |
- | Behavioral Problems Inheritance pattern (Unusual)
| |
- | Hyperactivity, tantrums Some obligate carrier males are
| |
- | Autistic features phenotypically normal. Referred to as “normal transmitting males” (NTM).
| |
- |
| |
- | 1/1250 males and 1/2000 females All ethnic groups
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | Promoter Exon 1 Exons 2-17
| |
- |
| |
- |
| |
- | ATG
| |
- | (CGG)n
| |
- |
| |
- | 5’ UTR
| |
- |
| |
- | The Fragile-X syndrome is caused by expansion of a triplet/trinucleotide (CGG) repeat in the 5’ untranslated region (UTR) of exon 1 of the FMR1 gene
| |
- |
| |
- | •
| |
- | The pathogenic mechanism appears to involve “loss of function” of the FMR1 gene or its gene product FMRP
| |
- |
| |
- | •
| |
- | Gene is expressed in neurons as well as oligodendrocytes (myelin producing cells of CNS)
| |
- |
| |
- | •
| |
- | FMRP is involved with the transport of mRNA of other genes
| |
- |
| |
- | •
| |
- | A similar syndrome can be caused by rare FMR1 point mutations (mutant protein)
| |
- |
| |
- |
| |
- |
| |
- | The expansion may be small (e.g., a “premutation”) or large (e.g., a “full mutation”) [see next slide]
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | Promoter Exon 1
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | Normal, n < 50 repeats promoter unmethylated
| |
- | Premutation, n ~ 50-200 promoter unmethylated
| |
- | Full mutation, n > 200 promoter methylated
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | x
| |
- |
| |
- | (CGG)n
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | (Rest of gene)
| |
- | Transcription
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | “Premutation” alleles are slightly expanded. The gene can still be transcribed, but, is potentially unstable and may expand further (e.g., to full mutation) in next generation
| |
- | Effect of different repeat sizes
| |
- |
| |
- | “Normal” alleles can vary inrepeat number
| |
- | Possibilities for exon 1
| |
- |
| |
- |
| |
- | “Full mutation” alleles have large expansions, are not transcribed, and cause Fragile- X syndrome
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | In addition to germline instability, there can be somatic instability and thus patients may be mosaics of cell populations with differing numbers of repeats
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | Wide upward diagonal
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | Normal transmitting male (NTM) - Has premutation
| |
- |
| |
- | Unaffected female: Heterozygous for full mutation and normal allele
| |
- |
| |
- |
| |
- | Affected male: Full mutation
| |
- | Females who are heterozygotes for a full mutation and normal allele may or may not develop the syndrome (~50% mentally retarded). Therefore, this disorder is not cleanly recessive or dominant.
| |
- |
| |
- |
| |
- |
| |
- | Wide upward diagonal
| |
- |
| |
- |
| |
- |
| |
- | Generally do not reproduce
| |
- |
| |
- |
| |
- | Female: Premutation Heterozygote
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | X
| |
- | Large FMR1 expansions to full mutations are usually not seen through fathers. There may be selection against passage of large alleles through the male germ line.
| |
- |
| |
- | Affected female:
| |
- | Heterozygous for full mutation and normal allele
| |
- |
| |
- |
| |
- |
| |
- | •
| |
- | Larger premutation alleles are more likely to expand Repeat size Risk of expansion 50-69 repeats <20 % 70-79 39 80-89 76 90-99 89 >99 >99 %
| |
- |
| |
- | •
| |
- | In addition, the CGG repeat region may be interrupted by AGG triplets in one or more places. Interrupted repeats appear to be less likely to expand than uninterrupted repeats.
| |
- |
| |
- |
| |
- |
| |
- | Risk of expansion during meiosis in female FMR1 premutation carriers
| |
- |
| |
- | More on premutations
| |
- | •
| |
- | Premutation carrier females are at 3-4 X increased risk for premature ovarian failure (POF) and early menopause.
| |
- |
| |
- |
| |
- |
| |
- | •Older premutation males may develop a neurodegenerative disorder known as Fragile X associated tremor/ataxia syndrome (FXTAS). May occur in 25% (or more ?) of premutation males > age 50 yrs. May also see in some female premutation carriers.
| |
- |
| |
- |
| |
- |
| |
- | •Some premutation carriers (perhaps as much as 25%) may have other manifestations such as mild cognitive and/or behavioral deficits.
| |
- |
| |
- | •So, the premutation state is not completely innocuous! –? RNA gain of negative function?
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | Polyglutamine tract (CAG) triplet repeat diseases
| |
- |
| |
- | Huntington disease
| |
- |
| |
- | Spinocerebellar ataxia (multiple types)
| |
- | Spinobulbar muscular atrophy
| |
- | Macado-Joseph disease
| |
- | Dentorubropallido dysplasia
| |
- |
| |
- | Tend to be neurologic,
| |
- | some demonstrate anticipation
| |
- |
| |
- | Triplet “repeats” also occur in coding regions (Result in poly “amino acid” tracts)
| |
- | It is estimated that ~ 20% of human proteins contain at least one such tract
| |
- |
| |
- |
| |
- | HD patient
| |
- | Autosomal dominant (Late onset) Clinical features: Progressive motor, cognitive and psychiatric abnormalities. Motor: Involuntary movements (chorea, 90% of patients) cannot be suppressed voluntarily. Rigidity later in disease. Cognitive: All aspects. Language later in course. Behavioral disturbances: Develop later in course. Aggression, apathy, sexual deviation Psychiatric: personality changes, affective psychosis, schizophrenia Survive 15-18 years after diagnosis
| |
- | Huntington Disease (Clinical case study #15 in text)
| |
- |
| |
- |
| |
- |
| |
- | Normal: 10-26 CAG repeats Premutation: 27-35 repeats Reduced penetrance: 36-41 repeats Repeat size correlates with age of onset Adult onset: 40-55 repeats Juvenile onset: >60 repeats Gender-specific anticipation New mutations are paternally derived 80% of juvenile cases are paternally derived Penetrance is high with larger mutant alleles (e.g., >40 repeats) and if live long enough. Ethical issues in genetic counseling (Presymptomatic testing)
| |
- | Huntington Disease Mostly inherited (97%), new mutation (3%)
| |
- |
| |
- | Polycystic kidney disease (Clinical case study # 22 in text)
| |
- |
| |
- | •
| |
- | Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common dominant diseases in man. 1 / 300 - 1000 births
| |
- |
| |
- |
| |
- | (Accounts for 8-10% of end-stage renal disease in US)
| |
- |
| |
- | •
| |
- | Average onset in 4th decade but can present earlier
| |
- |
| |
- | •
| |
- | 90% penetrant by age 70 yr
| |
- |
| |
- | •
| |
- | Renal: Cysts (100%, often bilateral) Blood in urine Adenomas Hypertension Kidney stones
| |
- |
| |
- |
| |
- |
| |
- | •Systemic disorder: can affect heart,
| |
- |
| |
- |
| |
- | liver, pancreas, cerebral vasculature
| |
- | •Polycystic liver common (75%)
| |
- |
| |
- |
| |
- | ~ 10 years after renal involvement.
| |
- |
| |
- | •Genes/mutations –PKD1 (Polycystin-1, 85% of cases) •Many different mutations
| |
- |
| |
- | •No common one, a high mutation rate
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | –PKD2 (Polycystin-2)
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | fig C-21 PKD
| |
- |
| |
- | Graphic
| |
- | NEJM 347:1504 (2002)
| |
- | MRI
| |
- |
| |
- |
| |
- | apkd mbid fig 215-10 cyst origin
| |
- | Heterozygous Zygote
| |
- | Somatic tissues, including kidney tubule epithelium
| |
- |
| |
- | Two Hits
| |
- | Light upward diagonal
| |
- | Cell division, development
| |
- |
| |
- | Light upward diagonal
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | Mut
| |
- | Norm
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | Second hit in one cell
| |
- |
| |
- |
| |
- | Cyst
| |
- | apkd mbid fig 215-10 cyst origin
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | •
| |
- | It has been found that in (at least some cases), there has been second hit that results in loss of function at the cellular level.
| |
- |
| |
- | •
| |
- | Second hit: (various possibilities) Mutation of normal allele Deletion of normal allele •
| |
- | Loss of Heterozygosity (LOH)
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | •
| |
- | Although two hits could also occur in a person who had not inherited a mutant allele, it would be rare.
| |
- |
| |
- | •
| |
- | Other factors besides a second hit may also impact cyst formation.
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | Neurofibromatosis (NF) (Two Types, I and II) (Type I is most common, Clinical case study #29 )
| |
- | Type I: Peripheral Neurofibromatosis
| |
- | (von Recklinhausen Disease)
| |
- | –
| |
- | Common, incidence of ca. 1 per 3500
| |
- |
| |
- | –
| |
- | Full penetrance, variable expressivity
| |
- |
| |
- | –
| |
- | Pleiotropy
| |
- |
| |
- |
| |
- |
| |
- | Neurologic, musculoskeletal, eye and
| |
- | skin abnormalities
| |
- | –
| |
- | Defining features
| |
- |
| |
- |
| |
- |
| |
- | Café au lait spots (skin hyperpigmentation, >95%)
| |
- | [first to appear, 6 or more for diagnosis]
| |
- | Neurofibromas (peripheral nerve tumor, >95%)
| |
- | [plexiform, subcutaneous, cutaneous]
| |
- | Lisch nodules (pigmented nodules of iris, 90-95%)
| |
- | –
| |
- | Increased risk for certain neoplasms
| |
- |
| |
- |
| |
- |
| |
- | Optic nerve glioma, brain tumors, malignant myeloid disorders
| |
- | –
| |
- | Also other features: E.g., axillary freckling (not exposed to sun)
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | NF clinical
| |
- | nf cafe-au-lait
| |
- | Neurofibromas
| |
- |
| |
- | Café au lait
| |
- | Lisch nodules
| |
- | Lisch nodules
| |
- |
| |
- | Pathogenesis
| |
- | Due to loss of function
| |
- | Can find “loss of heterozygosity” in some tumors (two hits)
| |
- | The activity of the normal allele is lost. Will hear of this idea again for cancer.
| |
- | May demonstrate segmental mosaicism
| |
- |
| |
- | NF1 gene (encodes neurofibromin) Over 500 different mutations About 50% are new (de novo) mutations (often unique to a family) ~ 80% of de novo are paternal (no apparent age effect) Typically a clinical diagnosis Tumor suppressor gene One function is to regulate Ras
| |
- | NF mosaic AJHG 81:243-251 2007
| |
- | NF AJHG 81-444 600
| |
- |
| |
- | Hemophilia A (X-linked recessive, clinical case study # 18)
| |
- | If have 25% of factor VIII – normal
| |
- |
| |
- | Minimal symptoms till < 5% factor VIII
| |
- |
| |
- | <1% factor VIII, severe disease
| |
- | (70% of cases)
| |
- | frequent bleeding
| |
- | (spontaneous or after minimal trauma)
| |
- | bleeding into joints (hemarthrosis) is
| |
- | common
| |
- |
| |
- | hemophilia text 7-18
| |
- | Gene: Large, 186 kb, 26 exons
| |
- | Variety of mutations (large or small deletions, insertions, missense, etc)
| |
- |
| |
- |
| |
- |
| |
- | •In 40-50% of severe cases, no FVIII mutation found by standard screens
| |
- |
| |
- |
| |
- |
| |
- | •Common inversion disrupts gene (~45% of cases)
| |
- |
| |
- |
| |
- |
| |
- | •Happens in male meiosis (paternal)
| |
- |
| |
- |
| |
- |
| |
- | Hemophilia A (cont) Unusual crossing over / recombination
| |
- | fig 6-2
| |
- | X chromosome before inversion
| |
- | See text page 180
| |
- |
| |
- | X chromosome after inversion
| |
- |
| |
- |
| |
- |
| |
- | Charcot-Marie-Tooth (CMT) disease (Hereditary motor and sensory neuropathy, HMSN) (Clinical case study # 6 in text)
| |
- |
| |
- | •
| |
- | Multiple HSMN types (dominant and recessive)
| |
- |
| |
- |
| |
- | - Clinically variable presentation / severity
| |
- |
| |
- | •Type 1 (Autosomal dominant, CMT1)
| |
- |
| |
- |
| |
- |
| |
- | – Slowly progressive distal wasting and weakness first in the legs (arms later), difficulty walking, loss of reflexes, loss of sensation in limbs fingers and toes.
| |
- |
| |
- | –Segmental demyelination of nerves of the peripheral nervous system (PNS) often accompanied by altered nerve conduction velocities, hypertrophic changes and “onion bulb” formation.
| |
- |
| |
- |
| |
- | •CMT1 frequently (70-80%) caused by duplication of the gene for a structural protein of PNS myelin, PMP-22.
| |
- |
| |
- |
| |
- |
| |
- | fig C-4 CMT
| |
- |
| |
- |
| |
- |
| |
- | Wide upward diagonal
| |
- | Wide upward diagonal
| |
- | Wide upward diagonal
| |
- | PMP-22
| |
- | PMP-22
| |
- | PMP-22
| |
- | Chr 17
| |
- |
| |
- |
| |
- |
| |
- | Wide upward diagonal
| |
- |
| |
- |
| |
- |
| |
- |
| |
- |
| |
- | X
| |
- |
| |
- | Repeated sequences on each side of gene lead to misalignment, recombination and gene duplication
| |
- | PMP-22
| |
- |
| |
- |
| |
- | fam hyperchol text 7-12
| |
- | LDL receptor
| |
- |
| |
- |
| |
- | Fig 11-11
| |
- | Globin
| |
- | Alpha globin deletions are a cause of alpha thalassemia
| |
- |
| |
- | End
| |